Leprosy Vaccine

An effective leprosy vaccine will save children like Marc Jun from a lifetime of suffering with this dreaded disease.

American Leprosy Missions is committed to bringing an END to leprosy by developing a leprosy vaccine that will stop this terrible disease before it even starts.

So in 2002, American Leprosy Missions began a partnership with the Infectious Disease Research Institute (IDRI) in Seattle, Washington to develop a vaccine for leprosy.

An investment of 15 years and more than $5 million has resulted in a vaccine that has started Phase I clinical safety trials in healthy human volunteers.

This is an exciting opportunity to partner with us to make a lasting difference in the world by opening the door to finally stopping this devastating disease.

Why is a leprosy vaccine needed?

  • This ancient disease is still disabling and isolating people.
  • Every two minutes someone is diagnosed with leprosy.
  • More than four million people in the world suffer from leprosy-related disabilities.
  • An effective vaccine will limit infection, prevent disease and reduce transmission.
  • A vaccine is the only way to end this terrible disease.

Thanks to your generous support, the leprosy vaccine Phase I clinical trial has begun.

Why now?

  • This is the first leprosy-specific vaccine to go through Phase I clinical trials.
  • We believe this vaccine will be an exciting new way to stop the transmission of leprosy and the only way to protect people from the disease long term.
  • What’s more, the vaccine may protect against nerve damage, the most serious complication of leprosy.
  • The vaccine has received approval from the U.S. Food and Drug Administration.

Why you?

  • This is an historic opportunity to help end an ancient disease.
  • With your help, families will never have to hear the devastating news that they have leprosy, nor suffer its debilitating effects.
  • You can leave a lasting legacy for millions of people around the world.

Funds needed

Thanks to your generous support, we have raised more than $1.2 million needed for the leprosy vaccine Phase I clinical trial.

This vaccine may be the most exciting breakthrough in leprosy treatment since the cure, multi-drug therapy, was launched in the 1980s. Together we have reached this historic moment. Thank you!

If you’d like to contribute to the leprosy vaccine, we only need $38,158 in order to finish the Phase I clinical trial and another $300,000 to launch the next phase among people most at risk. Donate now.

Progress and next steps

  • August 2017:  Approved by Food and Drug Administration 
  • October 2017:  Started Phase I clinical trial
  • November 2017: Interim safety review successfully completed
  • January-March 2018:  Complete injections of second cohort; perform last blood draw; begin one-year follow-up period
  • June-November 2018:  Complete clinical sample processing; analyze data and clinical immunology
  • March 2019:  Complete Phase I clinical trial
  • 2019:  Possible start of Phase II clinical trial in an endemic country

Leprosy vaccine in the news

Nature, March 28, 2018 – LepVax, a defined subunit vaccine that provides effective pre-exposure and post-exposure prophylaxis of M. leprae infection

Markets Insider, October 12, 2017 – Promising New Leprosy Vaccine Moves into Human Trials

Wisconsin State Journal, October 12, 2017 – Covance site of first human study of vaccine for leprosy

Join us – Together we can help end leprosy

By God’s grace and with your partnership, a vaccine will be able to spare children like Marc Jun the devastation and heartbreak of leprosy. Donate now to stop the suffering.